Product Description
An orally available morpholino-pyrimidine-based inhibitor of ataxia telangiectasia and rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration, ceralasertib selectively inhibits ATR activity by blocking the downstream phosphorylation of the serine/threonine protein kinase CHK1. This prevents ATR-mediated signaling, and results in the inhibition of DNA damage checkpoint activation, disruption of DNA damage repair, and the induction of tumor cell apoptosis. In addition, AZD6738 sensitizes tumor cells to chemo- and radiotherapy. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and survival; it is activated by DNA damage caused during DNA replication-associated stress. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ceralasertib)
Mechanisms of Action: ATR Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Belgium, Brazil, Canada, China, France, Germany, Hong Kong, Hungary, India, Ireland, Italy, Japan, Korea, Netherlands, Poland, Romania, Russia, Serbia, South Korea, Spain, Taiwan, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 25
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer
Phase 2: Ataxia Telangiectasia|Endometrial Cancer|Melanoma|Osteosarcoma|Pancreatic Cancer|Prostate Cancer|Renal Cell Carcinoma|Serous Cystadenocarcinoma|Small Cell Lung Cancer|Transitional Cell Carcinoma|Triple Negative Breast Cancer
Phase 1: Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Myelodysplastic Syndrome|Oncology Solid Tumor Unspecified|Preleukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| D533BC00001 | P3 |
Unknown Status |
Non-Small-Cell Lung Cancer |
2026-10-19 |
|
| LATIFY | P3 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2026-10-09 |
|
| D533AC00001 | P2 |
Unknown Status |
Melanoma |
2026-04-30 |
|
| STUDY00018504 | P2 |
Recruiting |
Triple Negative Breast Cancer |
2025-12-31 |